An unexpected story by Organon and Viatris

Organon, 5% growth from 5 years ago

Vitaris, No. 1 prescription for multinational corporations right after its launch

Lipitor, Celebrex, and Atozet have good sales regardless of generic release

Organon and Viatris' patent expired drugs remain powerful.

 

Although questions have been raised about the growth engines of the two independent corporations after receiving "old drugs" from MSD and Pfizer, it is evaluated that it is as good as in Korea.

 

◆Organon's Atozet and Cozaar's outpatient prescription is 250 billion won According to UBIST, a drug research institute, on the 28th, Organon, which was launched in June last year, exerted the power of patent-expired drugs.

 

Last year, Organon's outpatient prescription estimate was 252.4 billion won.

 

This is the sum of the outpatient prescriptions for items transferred to Organon among MSD products.

 

It accounts for 58% of the 437.5 billion won prescription for MSD.

 

The amount of outpatient prescriptions for Organon products grew 5.4% compared to 239.4 billion won in 2016.

 

Organon is a company spun off from MSD.

 

It took over Atozet, Cozaar, Singulair, and Nasonex, which are "Old Drugs." Most of Organon's products showed growth even though they were patented expired drugs that compete with generic products.

 

Atozet is a large item that recorded 86.8 billion won in outpatient prescriptions last year.

 

The number of prescriptions more than tripled over the past six years from 24.7 billion won in 2016.

 

Due to the expiration of patents in January last year, the release of more than 100 generics also rose 4.9% from the previous year.

 

Cozaar is an old drug that has been 25 years since its launch, and when generic was released in 2008, sales of 70 billion won collapsed.

 

However, sales of prescriptions have been on the rise again recently.

 

It increased 15.8% from 25.7 billion won in 2016 to 29.7 billion won last year.

 

In particular, Cozaar is one of the products that did not exceed the standard value during the Losartan impurity crisis last year.

 

The amount of prescriptions surged in December last year as demand flocked to the original due to concerns over impurities.Organone also has Propesia, a hair loss treatment.

 

It is widely used not only for prostate hypertrophy treatment but also for hair loss treatment as a non- reimbursed drug.

 

It is estimated that it generates more than 40 billion won in sales in Korea.

 

◆Lipitor, 22 years since its launch, 200 billion won in sales Founded in November 2020, Viatris posted the largest number of outpatient prescriptions among multinational pharmaceutical companies last year.

 

Viartris' outpatient prescription amount last year was 463.9 billion won, up 15.8% from 40.5 billion won in 2016.

 

Although it decreased 0.3% from the previous year, it is good compared to the 2 to 7% drop in prescriptions by many multinational pharmaceutical companies amid prolonged Corona.

 

Viatris is a company merged with Pfizer Upjohn and Mylan, a Pfizer patent expiration business.

 

Lipitor, Novasc, Lyrica, Cerebrex, and Viagra have been transferred to Viartris.

 

Lipitor has been 22 years since its launch, but it has been recorded as the most prescribed drug for the fourth consecutive year.

 

Lipitor recorded 205.2 billion won, an increase of 0.7% last year, after surpassing 200 billion won in outpatient prescriptions in 2020.

 

The scale has increased 23.4% from 2016.

 

Celebrex, a COX-2 inhibitor, also recorded 46.3 billion won in outpatient prescriptions, up 3.6% from the previous year.

 

At one time, the prescription amount fell to 36.5 billion won due to the launch of generic and the subsequent drop in drug prices, but has recovered to around 40 billion won since 2018.

 

Lyrica and Norvasc, which were released in 2006 and 1991, are still paying nearly 70 billion won in outpatient prescriptions.

 

The two products, worth 60.1 billion won and 62.6 billion won in 2016, respectively, grew 16.3% and 10.3% over six years.

 

◆ Price competitiveness and domestic business network When generics such as salt change items are released, the market share of original drugs drops rapidly.

 

However, in the domestic market, despite the intensive check of generics, original drugs that expire patents are showing off their robustness.

 

Due to the nature of the drug price system in Korea, generic's price competitiveness is low, so the original is advantageous for expanding its market share.

 

Market sales of patent-expired drugs have been established more firmly due to the sales price of domestic pharmaceutical companies.

 

Viatris' Lipitor, Lyrica, and Celebrex are jointly sold by Jeil.

 

Organon's Atozet is co-sold by Chong Kun Dang.